Accéder au contenu
Merck

Perinatal metabolism of vitamin D.

The American journal of clinical nutrition (2000-05-09)
B L Salle, E E Delvin, A Lapillonne, N J Bishop, F H Glorieux
RÉSUMÉ

During pregnancy, maternal serum concentrations of 25-hydroxyvitamin D, the circulating form of vitamin D, correlate with dietary vitamin D intake. Maternal serum concentrations of 1,25-dihydroxyvitamin D, the hormonal circulating and active form of vitamin D, are elevated during pregnancy; 1,25-dihydroxyvitamin D is synthesized mainly by the decidual cells of the placenta and allows for increased calcium absorption. The fetus is entirely dependent on the mother for its supply of 25-hydroxyvitamin D, which is believed to cross the placenta. Hypocalcemia and increased parathyroid hormone secretion induce synthesis of 1,25-dihydroxyvitamin D after birth in both full-term and preterm neonates. Nevertheless, serum concentrations of 25-hydroxyvitamin D are a rate-limiting factor in the synthesis of 1,25-dihydroxyvitamin D. In vitamin D-replete infants, circulating 1,25-dihydroxyvitamin D concentrations are higher than those observed in older infants. In countries where dairy products are not routinely supplemented with vitamin D, maternal vitamin D supplementation during pregnancy is necessary. However, there is no indication for the use of pharmacologic doses of vitamin D or its metabolites in the perinatal period.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Ergocalciferol, ≥98.0% (sum of enantiomers, HPLC)
Supelco
Ergocalciferol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Ergocalciferol, 40,000,000 USP units/g
Ergocalciferol, European Pharmacopoeia (EP) Reference Standard